TGFB1 and obesity due to melanocortin 4 receptor deficiency: New drugs acting on the TGFβ pathway could be suitable for use in the treatment of a variety of human diseases ranging from cancer, fibrosis and cardiovascular diseases to metabolic disorders like diabetes and obesity [41]–[47].